Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Low-Dose Tamoxifen for Mammographic Density Reduction : A Randomized Controlled Trial. / Eriksson, Mikael; Eklund, Martin; Borgquist, Signe; Hellgren, Roxanna; Margolin, Sara; Thoren, Linda; Rosendahl, Ann; Lång, Kristina; Tapia, José; Bäcklund, Magnus; Discacciati, Andrea; Crippa, Alessio; Gabrielson, Marike; Hammarström, Mattias; Wengström, Yvonne; Czene, Kamila; Hall, Per.

I: Journal of Clinical Oncology, Vol. 39, Nr. 17, 10.06.2021, s. 1899-1908.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Eriksson, M, Eklund, M, Borgquist, S, Hellgren, R, Margolin, S, Thoren, L, Rosendahl, A, Lång, K, Tapia, J, Bäcklund, M, Discacciati, A, Crippa, A, Gabrielson, M, Hammarström, M, Wengström, Y, Czene, K & Hall, P 2021, 'Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial', Journal of Clinical Oncology, vol. 39, nr. 17, s. 1899-1908. https://doi.org/10.1200/JCO.20.02598

APA

Eriksson, M., Eklund, M., Borgquist, S., Hellgren, R., Margolin, S., Thoren, L., Rosendahl, A., Lång, K., Tapia, J., Bäcklund, M., Discacciati, A., Crippa, A., Gabrielson, M., Hammarström, M., Wengström, Y., Czene, K., & Hall, P. (2021). Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. Journal of Clinical Oncology, 39(17), 1899-1908. https://doi.org/10.1200/JCO.20.02598

CBE

Eriksson M, Eklund M, Borgquist S, Hellgren R, Margolin S, Thoren L, Rosendahl A, Lång K, Tapia J, Bäcklund M, Discacciati A, Crippa A, Gabrielson M, Hammarström M, Wengström Y, Czene K, Hall P. 2021. Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. Journal of Clinical Oncology. 39(17):1899-1908. https://doi.org/10.1200/JCO.20.02598

MLA

Vancouver

Author

Eriksson, Mikael ; Eklund, Martin ; Borgquist, Signe ; Hellgren, Roxanna ; Margolin, Sara ; Thoren, Linda ; Rosendahl, Ann ; Lång, Kristina ; Tapia, José ; Bäcklund, Magnus ; Discacciati, Andrea ; Crippa, Alessio ; Gabrielson, Marike ; Hammarström, Mattias ; Wengström, Yvonne ; Czene, Kamila ; Hall, Per. / Low-Dose Tamoxifen for Mammographic Density Reduction : A Randomized Controlled Trial. I: Journal of Clinical Oncology. 2021 ; Vol. 39, Nr. 17. s. 1899-1908.

RIS

TY - JOUR

T1 - Low-Dose Tamoxifen for Mammographic Density Reduction

T2 - A Randomized Controlled Trial

AU - Eriksson, Mikael

AU - Eklund, Martin

AU - Borgquist, Signe

AU - Hellgren, Roxanna

AU - Margolin, Sara

AU - Thoren, Linda

AU - Rosendahl, Ann

AU - Lång, Kristina

AU - Tapia, José

AU - Bäcklund, Magnus

AU - Discacciati, Andrea

AU - Crippa, Alessio

AU - Gabrielson, Marike

AU - Hammarström, Mattias

AU - Wengström, Yvonne

AU - Czene, Kamila

AU - Hall, Per

PY - 2021/6/10

Y1 - 2021/6/10

N2 - PURPOSE: Tamoxifen prevents breast cancer in high-risk women and reduces mortality in the adjuvant setting. Mammographic density change is a proxy for tamoxifen therapy response. We tested whether lower doses of tamoxifen were noninferior to reduce mammographic density and associated with fewer symptoms.PATIENTS AND METHODS: Women, 40-74 years of age, participating in the Swedish mammography screening program were invited to the 6-month double-blind six-arm randomized placebo-controlled noninferiority dose-determination KARISMA phase II trial stratified by menopausal status (EudraCT 2016-000882-22). In all, 1,439 women were accrued with 1,230 participants accessible for intention-to-treat analysis. The primary outcome was proportion of women treated with placebo, 1, 2.5, 5, and 10 mg whose mammographic density decreased at least as much as the median reduction in the 20 mg arm. The noninferior margin was 17%. Secondary outcome was reduction of symptoms. Post hoc analyses were performed by menopausal status. Per-protocol population and full population were analyzed in sensitivity analysis.RESULTS: The 1,439 participants, 566 and 873 pre- and postmenopausal women, respectively, were recruited between October 1, 2016, and September 30, 2019. The participants had noninferior mammographic density reduction following 2.5, 5, and 10 mg tamoxifen compared with the median 10.1% decrease observed in the 20 mg group, a reduction confined to premenopausal women. Severe vasomotor symptoms (hot flashes, cold sweats, and night sweats) were reduced by approximately 50% in the 2.5, 5, and 10 mg groups compared with the 20 mg group.CONCLUSION: Premenopausal women showed noninferior magnitude of breast density decrease at 2.5 mg of tamoxifen, but fewer side effects compared with the standard dose of 20 mg. Future studies should test whether 2.5 mg of tamoxifen reduces the risk of primary breast cancer.

AB - PURPOSE: Tamoxifen prevents breast cancer in high-risk women and reduces mortality in the adjuvant setting. Mammographic density change is a proxy for tamoxifen therapy response. We tested whether lower doses of tamoxifen were noninferior to reduce mammographic density and associated with fewer symptoms.PATIENTS AND METHODS: Women, 40-74 years of age, participating in the Swedish mammography screening program were invited to the 6-month double-blind six-arm randomized placebo-controlled noninferiority dose-determination KARISMA phase II trial stratified by menopausal status (EudraCT 2016-000882-22). In all, 1,439 women were accrued with 1,230 participants accessible for intention-to-treat analysis. The primary outcome was proportion of women treated with placebo, 1, 2.5, 5, and 10 mg whose mammographic density decreased at least as much as the median reduction in the 20 mg arm. The noninferior margin was 17%. Secondary outcome was reduction of symptoms. Post hoc analyses were performed by menopausal status. Per-protocol population and full population were analyzed in sensitivity analysis.RESULTS: The 1,439 participants, 566 and 873 pre- and postmenopausal women, respectively, were recruited between October 1, 2016, and September 30, 2019. The participants had noninferior mammographic density reduction following 2.5, 5, and 10 mg tamoxifen compared with the median 10.1% decrease observed in the 20 mg group, a reduction confined to premenopausal women. Severe vasomotor symptoms (hot flashes, cold sweats, and night sweats) were reduced by approximately 50% in the 2.5, 5, and 10 mg groups compared with the 20 mg group.CONCLUSION: Premenopausal women showed noninferior magnitude of breast density decrease at 2.5 mg of tamoxifen, but fewer side effects compared with the standard dose of 20 mg. Future studies should test whether 2.5 mg of tamoxifen reduces the risk of primary breast cancer.

U2 - 10.1200/JCO.20.02598

DO - 10.1200/JCO.20.02598

M3 - Article

C2 - 33734864

VL - 39

SP - 1899

EP - 1908

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 17

ER -